| Business Summary | | Biomet,
Inc.
and
its
subsidiaries
design,
manufacture
and
market
products
used
primarily
by
musculoskeletal
medical
specialists
in
both
surgical
and
non-surgical
therapy,
including
reconstructive
and
fixation
devices,
electrical
bone
growth
stimulators,
orthopedic
support
devices,
operating
room
supplies,
general
surgical
instruments,
arthroscopy
products,
spinal
implants,
bone
cements,
bone
substitute
materials,
craniomaxillofacial
implants
and
instruments
and
dental
reconstructive
implants
and
associated
instrumentation. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Biomet,
Inc.
designs,
manufactures
and
markets
products
used
primarily
by
orthopedic
medical
specialists
in
both
surgical
and
non-surgical
therapy.
For
the
fiscal
year
ended
5/31/01,
net
sales
rose
12%
to
$1.03
billion.
Net
income
applicable
to
Common
rose
14%
to
$197.5
million.
Revenues
reflect
continued
penetration
of
the
reconstructive
device
market
and
higher
sales
of
spinal
products.
Earnings
also
reflect
improved
manufacturing
efficiencies. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Niles Noblitt, 49 Chairman | $407K | -- | Dane Miller, Ph. D., 54 Pres,
CEO | 404K | -- | Jerry Ferguson, 59 Vice
Chairman | -- | -- | Gregory Hartman, 43 Sr.
VP- Fin. and CFO | -- | -- | Charles Niemier, 44 Sr.
VP of International Operations | 387K | $221K | Dollar
amounts are as of 31-May-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|